Development and evaluation of a multivariable prediction model for clinical improvement in an established cohort of Colombian rheumatoid arthritis patients.
Claudia Ibáñez-Antequera, Gabriel-Santiago Rodríguez-Vargas, Fernando Rodríguez-Florido, Pedro Rodríguez-Linares, Adriana Rojas-Villarraga, Pedro Santos-Moreno
{"title":"Development and evaluation of a multivariable prediction model for clinical improvement in an established cohort of Colombian rheumatoid arthritis patients.","authors":"Claudia Ibáñez-Antequera, Gabriel-Santiago Rodríguez-Vargas, Fernando Rodríguez-Florido, Pedro Rodríguez-Linares, Adriana Rojas-Villarraga, Pedro Santos-Moreno","doi":"10.1177/1759720X251342426","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune disease, and a predicting clinical improvement is essential.</p><p><strong>Objectives: </strong>The aim of the present study was to identify predictor variables of clinical improvement in patients with RA using artificial intelligence (AI) models in a specialized RA center.</p><p><strong>Design: </strong>Retrospective cohort study in adult RA patients was conducted between January and June 2022. Follow-up data related to clinical improvement was taken from 6 to 12 months after the baseline. Predictive models were generated by machine learning (ML), by Python programming language. The Transparent Reporting of a multivariate prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines were followed to harmonize this study based on AI.</p><p><strong>Methods: </strong>The response variable was classified as improved and non-improved. Patients were considered improved if they persisted or achieved a Disease Activity Score 28-joints (DAS28) <3.2 at the end of the follow-up period or experienced a decrease ⩾0.6 compared to baseline, regardless of the initial DAS28 value. Explainability techniques in AI were applied to identify the most relevant clinical features.</p><p><strong>Results: </strong>In total, 3161 RA patients were included. The median age was 65 years (interquartile range (IQR) 57-72). 82.7% were female. Disease duration was 8.3 years (IQR 4.9-11.3). The median value of baseline DAS28 was 2.1 (IQR 2.1-2.8). 2668 (84.4%) were classified as improved, and 493 (15.6%) as non-improved. From ML models, the Extra tree model showed higher sensitivity (0.841). Regarding clinical improvement prediction with the Shapley Additive Explanations method, it was observed that low values of baseline DAS28 were positively associated with clinical improvement. The use of biologic disease-modifying antirheumatic drugs and the presence of anti-cyclic citrullinated peptide (CCP) were related to an increase in the probability of non-improved, which may be secondary to the level of severity of the disease.</p><p><strong>Conclusion: </strong>AI models in RA can predict clinical improvement at initial consultations, enabling targeted approaches. Disease severity may be influenced by anti-CCP positivity and the use of biologic therapies when conventional treatments fail.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"17 ","pages":"1759720X251342426"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174781/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Musculoskeletal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1759720X251342426","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease, and a predicting clinical improvement is essential.
Objectives: The aim of the present study was to identify predictor variables of clinical improvement in patients with RA using artificial intelligence (AI) models in a specialized RA center.
Design: Retrospective cohort study in adult RA patients was conducted between January and June 2022. Follow-up data related to clinical improvement was taken from 6 to 12 months after the baseline. Predictive models were generated by machine learning (ML), by Python programming language. The Transparent Reporting of a multivariate prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines were followed to harmonize this study based on AI.
Methods: The response variable was classified as improved and non-improved. Patients were considered improved if they persisted or achieved a Disease Activity Score 28-joints (DAS28) <3.2 at the end of the follow-up period or experienced a decrease ⩾0.6 compared to baseline, regardless of the initial DAS28 value. Explainability techniques in AI were applied to identify the most relevant clinical features.
Results: In total, 3161 RA patients were included. The median age was 65 years (interquartile range (IQR) 57-72). 82.7% were female. Disease duration was 8.3 years (IQR 4.9-11.3). The median value of baseline DAS28 was 2.1 (IQR 2.1-2.8). 2668 (84.4%) were classified as improved, and 493 (15.6%) as non-improved. From ML models, the Extra tree model showed higher sensitivity (0.841). Regarding clinical improvement prediction with the Shapley Additive Explanations method, it was observed that low values of baseline DAS28 were positively associated with clinical improvement. The use of biologic disease-modifying antirheumatic drugs and the presence of anti-cyclic citrullinated peptide (CCP) were related to an increase in the probability of non-improved, which may be secondary to the level of severity of the disease.
Conclusion: AI models in RA can predict clinical improvement at initial consultations, enabling targeted approaches. Disease severity may be influenced by anti-CCP positivity and the use of biologic therapies when conventional treatments fail.
期刊介绍:
Therapeutic Advances in Musculoskeletal Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of musculoskeletal disease.